January/February #185 : Cure: HDAC Inhibitors May Need Combos - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

Heart to Heart

Myths of Black MSM

From the Editor

Sowing the Seeds of Love

Feedback

Letters-January/February 2013

The POZ Q+A

Standing Against Stigma

POZ Planet

Storm Troopers

Say What-Fran Lebowitz

Oh No Canada

Signs of the Times

For Your Consideration...

Climb Every Mountain

Grindr IQ

Care and Treatment

Using Condoms As Directed

English Lessons

Comprehensive Care Is Possible

HIV, Meds and Booze

Research Notes

Cure: HDAC Inhibitors May Need Combos

Prevention: Revisiting HIV in Semen

Treatment: New Fusion Inhibitor, Integrase Inhibitor

POZ Survey Says

Full Disclosure

POZ Heroes

Minister of HIV

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

January / February 2013

Cure: HDAC Inhibitors May Need Combos

by Benjamin Ryan

Scientists have achieved a proof-of-concept that cancer drugs known as histone deacetylase (HDAC) inhibitors can flush HIV out of the long-elusive reservoirs where it hides out, latent, even during antiretroviral therapy. Histone deacetylase is an enzyme that helps suppress RNA expression in HIV, preventing ARVs from identifying and attacking the virus. Inhibiting these enzymes would be a key to flushing HIV out of hiding. Nancie Archin, PhD, and a team from the lab of David Margolis, MD, at the University of North Carolina at Chapel Hill School of Medicine have proved such an effect is possible with their study of eight people with HIV who each received three doses of the HDAC inhibitor Zolinza (vorinostat). Many questions about the efficacy and proper use of HDAC inhibitors remain, including concerns about potential toxicities and whether the drugs must be taken in combination with other agents to create a full cure. But this adds a vital piece of know-how to the vast puzzle of cure research.

Search: histone deacetylase inhibitors, HDAC inhibitors, Nancie Archin, Chapel Hill School of Medicine, Zolinza, vorinostat

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    dave41
    Bethany
    Oklahoma


    romanticseattle
    Tacoma
    Washington


    TaintedloveDC
    Washington
    DC


    HOTROD2010
    houston
    Texas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.